🔗 Share this article

As America continues making sweeping adjustments to its immunization schedules, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning coronavirus vaccines during the global health crisis and has concentrated on potential deaths after COVID-19 vaccination in her short tenure at the FDA.

Planned Overhauls to Childhood Immunization Program

Public health authorities planned to unveil major changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would put the US out of step with a large portion of the world with insufficient data for benefit. The announcement has been delayed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to run the center this calendar year.

A New Direction at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting specific pediatric shot schedules in the US in order to be more similar to Denmark, a society with universal health coverage and a citizenry about the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – typically the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Qualifications

The appointee has little discernible track record in medication creation, approval processes or leadership, which has been typical for past leaders of the CBER. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for running the CDER, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a major agency. She has no expertise in pharmaceutical oversight.”

Past heads of the center would “grasp legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the type of experience that former directors who led the center have had.”

This division has an enormous workload at the agency, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and all of those have to be looked after,” she noted. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the position, which manages in excess of 5,000 personnel. “It is a huge administrative position, if you perform it correctly,” Woodcock added.

Agency Reaction and Controversial Initiatives

When asked about questions about Dr. Høeg's qualifications and whether this appointment represents greater collaboration among agency officials on immunizations, a press secretary stated that the “questions stem from incorrect assumptions”.

“Her resume aligns with the duties of her role,” the representative explained, noting the period Høeg spent counseling the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a disputed expedited medication authorization process that apparently concerned her preceding directors. “By what process are these therapies being selected for this voucher program? Who makes the decisions?” Howard said. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the FDA seems to be moving towards laxer regulations of pharmaceuticals, except for immunizations.”

Established History on Immunizations

With immunizations, Høeg has a more established, if problematic, past, some experts said. She published a analysis using non-validated volunteer-provided data to determine the frequency of heart inflammation following Covid immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming administration included revising regulations for new vaccines and discontinuing “optional” vaccines, she remarked after the election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her conclusions and reverse-engineers to fit the science in a extremely disingenuous, untruthful way,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other contrarians, {like|